Xbrane Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 13.94 million compared to SEK 2.3 million a year ago. Net loss was SEK 41.88 million compared to SEK 45.47 million a year ago. Basic loss per share from continuing operations was SEK 1.69 compared to SEK 1.77 a year ago. Diluted loss per share from continuing operations was SEK 1.69 compared to SEK 1.77 a year ago. Basic loss per share was SEK 1.67 compared to SEK 1.83 a year ago. Diluted loss per share was SEK 1.67 compared to SEK 1.83 a year ago.
For the nine months, sales was SEK 36.76 million compared to SEK 7.64 million a year ago. Net loss was SEK 111.78 million compared to SEK 155.91 million a year ago. Basic loss per share from continuing operations was SEK 4.51 compared to SEK 6.5 a year ago. Diluted loss per share from continuing operations was SEK 4.51 compared to SEK 6.5 a year ago. Basic loss per share was SEK 4.45 compared to SEK 6.75 a year ago. Diluted loss per share was SEK 4.45 compared to SEK 6.75 a year ago.